Glenmark Pharma launches Ryaltris nasal spray for allergic rhintis in US

British drugmaker Hikma to distribute Ryaltris while Glenmark will manufacture it

Glenmark Pharmaceuticals’ US arm has launched the only-approved fixed-dose combination therapy for seasonal allergic rhinitis in the US market. This Ryaltris nasal spray will be distributed by British drug major Hikma Pharmaceuticals.

Brendan O’Grady, chief executive officer (CEO) of Global Formulations Business, Glenmark Pharmaceuticals, told Business Standard that the wholesale acquisition cost price for Ryaltris will be kept around $210.

“Considering the co-pay mechanism until Ryaltris is covered under the insurance, patients will have to pay around $49 out of their pockets,” he added. Glenmark holds the new drug application for Ryaltris in the US.

It will manufacture and supply